The Food and Drug Administration has approved an antipsychotic drug that carries a digital sensor to track whether patients are taking it, according to an agency announcement published Monday.

The new drug, Abilify MyCite, is used to treat schizophrenia and manic episodes associated with bipolar disorder. After a patient has swallowed it and once the medication reaches the stomach, a sensor sends a message to a wearable patch, which then transfers information onto a mobile app.